Navigation Links
Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Date:8/20/2007

aring two dose levels of OxyADF Tablets to placebo. Study medication will be administered to patients every six hours for 48 hours following the onset of moderate to severe pain following bunionectomy surgery. Study 105 is targeted to enroll 135 patients per arm (approximately 405 patients in total). As previously announced, the Company executed a Clinical Trial Development Agreement with a leading Contract Research Organization and commenced preliminary Study 105 start-up activities. However, initiation of patient enrollment in Study 105 remained dependent upon the availability of adequate funding. Now that new funding has been secured, the Company intends to proceed with patient enrollment in Study 105. The Company believes the completion of Study 105 is the critical time and events path to a 505(b)(2) NDA submission for OxyADF Tablets.

About Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of innovative Aversion(R) (abuse deterrent) Technology and related product candidates.

Forward Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. The most significant of such risks and uncertainties include, but are not limited to, the Company's ability to secure additional financing to fund operations, the Company's ability to enter into contractual arrangements with qualified pharmaceutical partners to license, develop and commercialize the Company's technology and product candidates, the Company's ability to avoid infringement of patents, trademarks and other proprietary rights or trade secrets of third parties, and the Company
'/>"/>

SOURCE Acura Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Results of the ... Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin Detection ... session at the 32 nd Annual Miami Breast ... conducted by Moshe Papa , MD, FACS, Professor ... Tel Aviv University, reports an analysis of MarginProbe,s efficiency ...
(Date:3/4/2015)... , March 4, 2015   HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that CEO Doug Godshall is scheduled ... at 8:00 a.m. Eastern Time on Tuesday, March 10, ... the Loews Miami Beach Hotel in Florida ...
(Date:3/4/2015)... Deutschland, 4. März 2015 TeraRecon, ... medizinischen Bildmanagementlösungen für Unternehmen, baut seine Präsenz ... Sternberg zum Director of Sales und ... weiter aus. Logo - ... ist für den Verkauf und die ...
Breaking Medicine Technology:New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be Webcast 2TeraRecon baut seine Präsenz in EMEA aus 2TeraRecon baut seine Präsenz in EMEA aus 3
... publishing and,information services company focused on market research ... the Asia-Pacific region is grabbing an,increasing share of ... changes across the region, has already been growing ... to the new 160-plus page report from CenterWatch ...
... In response to the growing,need for competent ... certificate program in Clinical Research and Regulatory,Administration ... of Continuing Studies (SCS), in,partnership with Northwestern ... launch the new program this spring with ...
Cached Medicine Technology:Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report 2Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report 3Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program 2
(Date:3/4/2015)... (PRWEB) March 04, 2015 The federal ... allege the statin drug caused patients to develop Type ... District Court, District of South Carolina. According to court ... on March 26, 2015 at 10:00 a.m. In advance ... submit a Joint Status report to the Court by ...
(Date:3/4/2015)... The ability of volumetric breast imaging ... help improve breast cancer risk prediction models is ... at the European Congress of Radiology (ECR) meeting, ... posters and 2 session presentations - highlight the ... quantitative breast imaging software tools to provide insight ...
(Date:3/4/2015)... York (PRWEB) March 04, 2015 More ... the cardiovascular risks potentially associated with low testosterone treatments ... (FDA) announced that it will now require manufacturers to ... their risk for heart attacks and strokes. In a ... the agency also stated that it was requiring testosterone ...
(Date:3/4/2015)... March 04, 2015 The print component ... The San Francisco Chronicle with a circulation of approximately ... Its digital component is distributed nationally through a vast ... news sites and partner outlets. To explore the digital ... , Milorganite is composed of heat-dried microbes that have ...
(Date:3/4/2015)... The Global Liquefied Petroleum Gas Market was ... estimated to grow to $288.7 billion by 2019, ... 2019. , Browse through the TOC of Global ... industry trends, segments & forecasts., http://www.micromarketmonitor.com/market-report/liquid-petroleum-gas-reports-5046983367.html ... is classified into source, application, and region. The ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Starting the morning of Feb. 1, two,giant heart-shaped ... of,Michigan,s downtown Detroit headquarters building and remind women to ... February, the 11-story high heart displays will adorn both,the ... on East,Lafayette near I-375 in downtown Detroit. The large ...
... University of Oregon scientists say they have identified a ... cells to form into muscles in zebrafish. , Much ... go to lunch, the trigger gene, which is identified ... for muscle formation to begin, a process known as ...
... of Alabama at Birmingham have uncovered important new information about ... replicate and wreak havoc on the immune system. , The ... viruses work to subvert the immune system, the researchers say. ... used to develop new drugs to combat a variety of ...
... most hospitals already stocked with simple, inexpensive solution , , THURSDAY, ... (magnesium sulfate) given just before delivery to pregnant women at ... palsy among these newborns in half, U.S. researchers report. , ... United States. All the women were at high risk for ...
... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
... Jan. 31 MQ Associates, Inc. ("MQ,Associates") announced ... tender offer and consent solicitation with respect to ... (CUSIP No. 55345RAC2) (the "Notes").,The tender offer and ... on January 29, 2008 (the "Expiration Date")., ...
Cached Medicine News:Health News:Heart-Shaped Light Displays on Blue Cross Blue Shield of Michigan Building Show Support for American Heart Month, National Wear Red Day 2Health News:Oregon researchers find trigger gene for muscle development 2Health News:Researchers uncover more about how poxviruses evade the immune system 2Health News:Researchers uncover more about how poxviruses evade the immune system 3Health News:Epsom Salt Cut Cerebral Palsy Rate in Half Among Preemies 2Health News:MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012 2Health News:MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012 3
Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
Round knurled handle. Overall length 130 mm....
4.625 inches, curved blade 4 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: